Mitochondrial bioenergetics is associated with aggressive breast cancer growth

线粒体生物能学与侵袭性乳腺癌生长相关

基本信息

  • 批准号:
    10082438
  • 负责人:
  • 金额:
    $ 35.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-01-01 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

Although metastatic breast cancer is still an incurable disease, the increasing understanding of the molecular biology of metastatic disease has allowed the development of therapies aimed at specific molecular targets. To elucidate the mechanistic insights of radioresistant breast cancer cells especially the cancer stem cells will provide important information to define effective radiosensitization targets. Instead of the currently believed aerobic glycolysis, we propose to test a paradigm shifting idea that mitochondrial bioenergetics is the major cellular fuel supply for aggressive cancer growth, especially in the radioresistant breast cancer stem cells. A milestone work from the PI's lab identified a fraction of breast cancer stem cells (BCSCs) expressing HER2 (HER2+ BCSCs) in the radiation-surviving breast cancer cells and in the recurrent/metastatic breast tumors. A unique metabolic feature of HER2+ BCSCs is characterized by a shift from the aerobic glycolysis dominant (Warburg effect) to the mitochondrial governed bioenergetics under radiation insult. Such stress-induced reprogramming of mitochondrial energy boost requires the mitochondrial relocation of CDK1 and phosphorylation of a myriad of critical CDK1 targets inside the mitochondria (i.e., STAT3, SIRT3, complex I subunits, MnSOD). Translocation of normally nuclear cell cycle kinase CDK1 into the mitochondria for enhancing the mitochondrial bioenergetics is a pioneer work in the field of mitochondria and has many implications for tumor metabolism. Cells harboring deficient mitochondria-specific CDK1 showed reduced survival after radiation. These results indicate a new metabolic mechanism by which CDK1 acting upon its mitochondrial targets up-regulates mitochondrial energy output for HER2+ BCSCs to survive and adapt to the therapeutic circumstances, causing aggressive and resistant behavior. The central hypothesis is that activation of CDK1 enhances mitochondrial bioenergetics, leading to the increased capacity of DNA repair and aggressive growth of HER2+ BCSCs; blocking CDK1-mediated mitochondrial bioenergetics is an effective approach to re-sensitize breast tumors to radiation. There are Three Specific Aims: Aim 1. Characterize mitochondrial biogenetics in irradiated breast cancer cells. Aim 2. Investigate CDK1-mediated mitochondrial bioenergetics in HER2+ BCSCs. Aim 3. Evaluate radiosensitization of HER2+ BCSCs by blocking CDK1-mediated mitochondrial bioenergetics. The overarching goals of this proposal are to study how CDK1 regulates the reprogramming of mitochondrial bioenergetics causing radioresistance of breast cancer stem cells HER2+ BCSCs. Subsequently, the mitochondrial CDK1 and/or its key mitochondria substrates will be identified as aspecific molecular target for radiosensitization of resistant breast cancer.
尽管转移性乳腺癌仍然是一种无法治愈的疾病,但对转移性疾病分子生物学的日益了解使得针对特定分子靶点的治疗方法得以发展。阐明乳腺癌细胞特别是肿瘤干细胞的耐辐射机制将为确定有效的放射增敏靶点提供重要信息。与目前认为的有氧糖酵解不同,我们提出测试一种范式转变的观点,即线粒体生物能量是侵袭性癌症生长的主要细胞燃料供应,特别是在耐辐射的乳腺癌干细胞中。PI实验室的一项里程碑式的工作发现了一小部分

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jian Jian Li其他文献

Jian Jian Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jian Jian Li', 18)}}的其他基金

A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis
用于治疗放射性直肠炎的脱细胞猪胎盘基质水凝胶
  • 批准号:
    10599727
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Target MKP-1 for Therapy-Resistant Breast Cancer Stem Cells
治疗耐药乳腺癌干细胞的靶点 MKP-1
  • 批准号:
    8255464
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:
Target MKP-1 for Therapy-Resistant Breast Cancer Stem Cells
治疗耐药乳腺癌干细胞的靶点 MKP-1
  • 批准号:
    8113116
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:
Target MKP-1 for Therapy-Resistant Breast Cancer Stem Cells
治疗耐药乳腺癌干细胞的靶点 MKP-1
  • 批准号:
    8634735
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:
Target MKP-1 for Therapy-Resistant Breast Cancer Stem Cells
治疗耐药乳腺癌干细胞的靶点 MKP-1
  • 批准号:
    8450278
  • 财政年份:
    2011
  • 资助金额:
    $ 35.91万
  • 项目类别:
NF-kB-mediated HER-2 overexpression in radioresistant breast cancer stem cells?
NF-kB 介导的 HER-2 在放射抗性乳腺癌干细胞中过度表达?
  • 批准号:
    7937029
  • 财政年份:
    2009
  • 资助金额:
    $ 35.91万
  • 项目类别:
NF-kB-mediated HER-2 overexpression in radioresistant breast cancer stem cells?
NF-kB 介导的 HER-2 在放射抗性乳腺癌干细胞中过度表达?
  • 批准号:
    7729968
  • 财政年份:
    2009
  • 资助金额:
    $ 35.91万
  • 项目类别:
NF-kB-mediated HER-2 overexpression in radioresistant breast cancer stem cells?
NF-kB 介导的 HER-2 在放射抗性乳腺癌干细胞中过度表达?
  • 批准号:
    8116556
  • 财政年份:
    2009
  • 资助金额:
    $ 35.91万
  • 项目类别:
NF-kB-mediated HER-2 overexpression in radioresistant breast cancer stem cells?
NF-kB 介导的 HER-2 在放射抗性乳腺癌干细胞中过度表达?
  • 批准号:
    8310068
  • 财政年份:
    2009
  • 资助金额:
    $ 35.91万
  • 项目类别:
NF-kB-mediated HER-2 overexpression in radioresistant breast cancer stem cells?
NF-kB 介导的 HER-2 在放射抗性乳腺癌干细胞中过度表达?
  • 批准号:
    8504735
  • 财政年份:
    2009
  • 资助金额:
    $ 35.91万
  • 项目类别:

相似海外基金

Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
  • 批准号:
    10590611
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中的骨-脂肪相互作用
  • 批准号:
    10706006
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
  • 批准号:
    10368975
  • 财政年份:
    2021
  • 资助金额:
    $ 35.91万
  • 项目类别:
BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism
BCCMA:针对和抵抗不利于骨骼的条件的基础研究(遏制骨折):长效 PTH 和拟钙剂联合作用对骨骼合成代谢的作用
  • 批准号:
    10365254
  • 财政年份:
    2021
  • 资助金额:
    $ 35.91万
  • 项目类别:
Bone-Adipose Interactions During Skeletal Anabolism
骨骼合成代谢过程中骨-脂肪相互作用
  • 批准号:
    10202896
  • 财政年份:
    2021
  • 资助金额:
    $ 35.91万
  • 项目类别:
BCCMA: Foundational Research to Act Upon and Resist Conditions Unfavorable to Bone (FRACTURE CURB): Combined long-acting PTH and calcimimetics actions on skeletal anabolism
BCCMA:针对和抵抗不利于骨骼的条件的基础研究(遏制骨折):长效 PTH 和拟钙剂联合作用对骨骼合成代谢的作用
  • 批准号:
    10531570
  • 财政年份:
    2021
  • 资助金额:
    $ 35.91万
  • 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
  • 批准号:
    10541847
  • 财政年份:
    2019
  • 资助金额:
    $ 35.91万
  • 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
  • 批准号:
    10319573
  • 财政年份:
    2019
  • 资助金额:
    $ 35.91万
  • 项目类别:
Dissecting molecular mechanisms implicated in age- and osteoarthritis-related decline in anabolism in articular cartilage
剖析与年龄和骨关节炎相关的关节软骨合成代谢下降有关的分子机制
  • 批准号:
    10062790
  • 财政年份:
    2019
  • 资助金额:
    $ 35.91万
  • 项目类别:
Promotion of NAD+ anabolism to promote lifespan
促进NAD合成代谢以延长寿命
  • 批准号:
    DE170100628
  • 财政年份:
    2017
  • 资助金额:
    $ 35.91万
  • 项目类别:
    Discovery Early Career Researcher Award
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了